I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Although it appears not to cause more severe illness, preliminary data demonstrate that the variant exhibits significant ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Moderna was recently told that the Health and Human Services Department (HHS) had withdrawn a $766million grant awarded by ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...